ZA200601386B - Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer - Google Patents
Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer Download PDFInfo
- Publication number
- ZA200601386B ZA200601386B ZA200601386A ZA200601386A ZA200601386B ZA 200601386 B ZA200601386 B ZA 200601386B ZA 200601386 A ZA200601386 A ZA 200601386A ZA 200601386 A ZA200601386 A ZA 200601386A ZA 200601386 B ZA200601386 B ZA 200601386B
- Authority
- ZA
- South Africa
- Prior art keywords
- parp
- cells
- cancer
- gene
- nucleic acid
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 230000000694 effects Effects 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title claims description 112
- 206010028980 Neoplasm Diseases 0.000 title claims description 56
- 201000011510 cancer Diseases 0.000 title claims description 43
- 108091030071 RNAI Proteins 0.000 title claims description 24
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 title claims description 7
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 title description 2
- 230000006801 homologous recombination Effects 0.000 claims abstract description 58
- 238000002744 homologous recombination Methods 0.000 claims abstract description 58
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 32
- 230000008439 repair process Effects 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 231100001074 DNA strand break Toxicity 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims abstract description 8
- 108090000790 Enzymes Proteins 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 230000007547 defect Effects 0.000 claims abstract description 6
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims description 111
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims description 111
- 230000002950 deficient Effects 0.000 claims description 59
- 108700020462 BRCA2 Proteins 0.000 claims description 44
- 102000052609 BRCA2 Human genes 0.000 claims description 44
- 101150008921 Brca2 gene Proteins 0.000 claims description 44
- 239000012661 PARP inhibitor Substances 0.000 claims description 25
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 25
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- -1 RPAI Proteins 0.000 claims description 18
- 230000009368 gene silencing by RNA Effects 0.000 claims description 18
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 13
- 230000006907 apoptotic process Effects 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 11
- 102000036365 BRCA1 Human genes 0.000 claims description 10
- 108700020463 BRCA1 Proteins 0.000 claims description 9
- 101150072950 BRCA1 gene Proteins 0.000 claims description 9
- 230000035772 mutation Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 claims description 7
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 claims description 7
- 230000002068 genetic effect Effects 0.000 claims description 7
- 230000006798 recombination Effects 0.000 claims description 7
- 238000005215 recombination Methods 0.000 claims description 7
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 claims description 6
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 claims description 6
- 108700025695 Suppressor Genes Proteins 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 claims description 4
- 101710176890 Protein ADP-ribosyltransferase PARP3 Proteins 0.000 claims description 4
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 claims description 4
- 101710204718 Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 claims description 4
- 230000009395 genetic defect Effects 0.000 claims description 4
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 claims description 3
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 claims description 3
- 101710129674 Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 claims description 3
- 101710204725 Protein mono-ADP-ribosyltransferase PARP4 Proteins 0.000 claims description 3
- 102100034931 Protein mono-ADP-ribosyltransferase PARP4 Human genes 0.000 claims description 3
- 108010049290 ADP Ribose Transferases Proteins 0.000 claims description 2
- 102000000872 ATM Human genes 0.000 claims description 2
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 claims description 2
- 102100035631 Bloom syndrome protein Human genes 0.000 claims description 2
- 108091009167 Bloom syndrome protein Proteins 0.000 claims description 2
- 101150006084 CHKB gene Proteins 0.000 claims description 2
- 101710083734 CTP synthase Proteins 0.000 claims description 2
- 102100039866 CTP synthase 1 Human genes 0.000 claims description 2
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 claims description 2
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims description 2
- 102100026121 Flap endonuclease 1 Human genes 0.000 claims description 2
- 108090000652 Flap endonucleases Proteins 0.000 claims description 2
- 102100035184 General transcription and DNA repair factor IIH helicase subunit XPD Human genes 0.000 claims description 2
- 101000770953 Homo sapiens DNA repair endonuclease XPF Proteins 0.000 claims description 2
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 claims description 2
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 claims description 2
- 101000977270 Homo sapiens MMS19 nucleotide excision repair protein homolog Proteins 0.000 claims description 2
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims description 2
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims description 2
- 101001113440 Homo sapiens Poly [ADP-ribose] polymerase 2 Proteins 0.000 claims description 2
- 101000709305 Homo sapiens Replication protein A 14 kDa subunit Proteins 0.000 claims description 2
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 claims description 2
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100023474 MMS19 nucleotide excision repair protein homolog Human genes 0.000 claims description 2
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 101150101566 Parp gene Proteins 0.000 claims description 2
- 101710129670 Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 102100034372 Replication protein A 14 kDa subunit Human genes 0.000 claims description 2
- 102100035525 Replication protein A 32 kDa subunit Human genes 0.000 claims description 2
- 101000770949 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) 3'-flap repair endonuclease Xpf Proteins 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102100035336 Werner syndrome ATP-dependent helicase Human genes 0.000 claims description 2
- 108010000443 X-ray Repair Cross Complementing Protein 1 Proteins 0.000 claims description 2
- 102000002258 X-ray Repair Cross Complementing Protein 1 Human genes 0.000 claims description 2
- 102100036973 X-ray repair cross-complementing protein 5 Human genes 0.000 claims description 2
- 101710124921 X-ray repair cross-complementing protein 5 Proteins 0.000 claims description 2
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 2
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 102000009062 ADP Ribose Transferases Human genes 0.000 claims 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims 1
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims 1
- 101150100766 MUS81 gene Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 142
- 230000010076 replication Effects 0.000 description 29
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 15
- 230000003902 lesion Effects 0.000 description 15
- 230000005782 double-strand break Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 11
- 108091026813 Poly(ADPribose) Proteins 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 11
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 11
- 229940104230 thymidine Drugs 0.000 description 11
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 9
- 229960001330 hydroxycarbamide Drugs 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 8
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 5
- 101100139868 Floropilus chiversii rads1 gene Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000011813 knockout mouse model Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- 230000004543 DNA replication Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000005731 poly ADP ribosylation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 239000012623 DNA damaging agent Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000033590 base-excision repair Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000005025 clonogenic survival Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- MBABOKRGFJTBAE-UHFFFAOYSA-N methyl methanesulfonate Chemical compound COS(C)(=O)=O MBABOKRGFJTBAE-UHFFFAOYSA-N 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108700010154 BRCA2 Genes Proteins 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101100300807 Drosophila melanogaster spn-A gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 101150030450 IRS1 gene Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000007999 Nuclear Proteins Human genes 0.000 description 2
- 108010089610 Nuclear Proteins Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000033443 single strand break repair Effects 0.000 description 2
- 230000005783 single-strand break Effects 0.000 description 2
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002723 toxicity assay Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- XIZCDQOKKYYCRH-UHFFFAOYSA-N 1h-benzimidazole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=NC2=C1 XIZCDQOKKYYCRH-UHFFFAOYSA-N 0.000 description 1
- JJDMKDXGNVJWCD-UHFFFAOYSA-N 1h-benzimidazole-4-carboxamide Chemical class NC(=O)C1=CC=CC2=C1N=CN2 JJDMKDXGNVJWCD-UHFFFAOYSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- GGQYZNMUKWBANT-UHFFFAOYSA-N 4-[3-[(3,4-dihydroxyphenyl)methyl]-4-hydroxy-2-(hydroxymethyl)butyl]benzene-1,2-diol Chemical compound C=1C=C(O)C(O)=CC=1CC(CO)C(CO)CC1=CC=C(O)C(O)=C1 GGQYZNMUKWBANT-UHFFFAOYSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241001263092 Alchornea latifolia Species 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100407073 Caenorhabditis elegans parp-1 gene Proteins 0.000 description 1
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 102100021242 Dymeclin Human genes 0.000 description 1
- 201000004939 Fanconi anemia Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000033640 Hereditary breast cancer Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 description 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 description 1
- 101000817629 Homo sapiens Dymeclin Proteins 0.000 description 1
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 description 1
- 101001113483 Homo sapiens Poly [ADP-ribose] polymerase 1 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 1
- 102000001195 RAD51 Human genes 0.000 description 1
- 101150023114 RNA1 gene Proteins 0.000 description 1
- 108010068097 Rad51 Recombinase Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 108010017601 Tankyrases Proteins 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 101150097643 Xrcc2 gene Proteins 0.000 description 1
- 101150040777 Xrcc3 gene Proteins 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 208000036878 aneuploidy Diseases 0.000 description 1
- 231100001075 aneuploidy Toxicity 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000013557 cerebral hemisphere cancer Diseases 0.000 description 1
- 201000008860 cerebrum cancer Diseases 0.000 description 1
- KOUGHMOSYJCJLE-UHFFFAOYSA-N chembl131719 Chemical compound N=1C=2C(C(=O)N)=CC=CC=2NC=1C1=CC=C(O)C=C1 KOUGHMOSYJCJLE-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ISNBJLXHBBZKSL-UHFFFAOYSA-N ethyl n-[2-(1,3-benzothiazole-2-carbonylamino)thiophene-3-carbonyl]carbamate Chemical compound C1=CSC(NC(=O)C=2SC3=CC=CC=C3N=2)=C1C(=O)NC(=O)OCC ISNBJLXHBBZKSL-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 1
- 230000001145 hyperrecombinational effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- LFUJIPVWTMGYDG-UHFFFAOYSA-N isoquinoline-1,5-diol Chemical compound N1=CC=C2C(O)=CC=CC2=C1O LFUJIPVWTMGYDG-UHFFFAOYSA-N 0.000 description 1
- 150000002537 isoquinolines Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- LQZPJQKYAOYUJS-UHFFFAOYSA-N n,n-diethyl-2-phenothiazin-10-ylethanamine;hydron;chloride Chemical compound Cl.C1=CC=C2N(CCN(CC)CC)C3=CC=CC=C3SC2=C1 LQZPJQKYAOYUJS-UHFFFAOYSA-N 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 230000008689 nuclear function Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- RZFVLEJOHSLEFR-UHFFFAOYSA-N phenanthridone Chemical compound C1=CC=C2C(O)=NC3=CC=CC=C3C2=C1 RZFVLEJOHSLEFR-UHFFFAOYSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011127 radiochemotherapy Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 231100000188 sister chromatid exchange Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 208000027223 tetraploidy syndrome Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Lubricants (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0317466.1A GB0317466D0 (en) | 2003-07-25 | 2003-07-25 | Use |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200601386B true ZA200601386B (en) | 2007-04-25 |
Family
ID=27772701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200601386A ZA200601386B (en) | 2003-07-25 | 2006-02-16 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Country Status (19)
Country | Link |
---|---|
US (5) | US8859562B2 (ja) |
EP (1) | EP1649017B2 (ja) |
JP (3) | JP5519097B2 (ja) |
KR (1) | KR101136702B1 (ja) |
CN (3) | CN1856313B (ja) |
AT (1) | ATE516353T1 (ja) |
AU (1) | AU2004261779B2 (ja) |
BR (1) | BRPI0412909B1 (ja) |
CA (1) | CA2533423C (ja) |
DK (1) | DK1649017T4 (ja) |
ES (1) | ES2367433T5 (ja) |
GB (2) | GB0317466D0 (ja) |
HK (2) | HK1094006A1 (ja) |
NO (1) | NO338398B1 (ja) |
NZ (1) | NZ545307A (ja) |
PL (1) | PL1649017T5 (ja) |
PT (1) | PT1649017E (ja) |
WO (1) | WO2005012524A1 (ja) |
ZA (1) | ZA200601386B (ja) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
US7217709B2 (en) | 2003-02-28 | 2007-05-15 | Inotek Pharmaceuticals Corporation | Tetracyclic benzamide derivatives and methods of use thereof |
DK1660095T3 (da) | 2003-07-25 | 2010-05-25 | Cancer Rec Tech Ltd | Tricykliske PARP-inhibitorer |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
RU2413515C2 (ru) * | 2003-12-01 | 2011-03-10 | Кудос Фармасьютикалс Лимитед | Ингибиторы репарации повреждения днк для лечения рака |
US20060204981A1 (en) * | 2005-01-07 | 2006-09-14 | Chiang Li | Compositions for modulation of PARP and methods for screening for same |
MX2007008771A (es) | 2005-01-19 | 2007-09-11 | Mgi Gp Inc | Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp. |
WO2006093667A1 (en) | 2005-02-25 | 2006-09-08 | Inotek Pharmaceuticals Corporation | Tetracyclic amino and carboxamido compounds and methods of use thereof |
BRPI0615096A2 (pt) | 2005-08-24 | 2009-07-14 | Inotek Pharmaceuticals Corp | análogos de indenoisoquinolinona e métodos de uso dos mesmos |
ES2361566T3 (es) * | 2005-11-25 | 2011-06-20 | Pharma Mar S.A., Sociedad Unipersonal | Uso de inhibidores de parp-1. |
EP2092083A2 (en) | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
ES2529147T3 (es) * | 2006-12-26 | 2015-02-17 | Pharmacyclics, Inc. | Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación |
AU2008221358A1 (en) | 2007-02-28 | 2008-09-04 | Inotek Pharmaceuticals Corporation | Indenoisoquinolinone analogs and methods of use thereof |
GB0707556D0 (en) * | 2007-04-19 | 2007-05-30 | Isis Innovation | Treatment for cancer |
JP5335673B2 (ja) | 2007-06-20 | 2013-11-06 | 学校法人 埼玉医科大学 | 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
WO2009027650A1 (en) * | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
KR101596526B1 (ko) | 2007-10-03 | 2016-02-22 | 에이자이 아이엔씨. | Parp 억제제 화합물, 조성물 및 사용 방법 |
JP5683261B2 (ja) | 2008-03-11 | 2015-03-11 | 学校法人 埼玉医科大学 | 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬 |
KR20110128785A (ko) * | 2008-10-24 | 2011-11-30 | 매그나켐 인터내셔널 레버러토리즈 아이엔씨 | Rad9와 선택적으로 상호작용하는 화합물들의 스크리닝방법 |
US8435961B2 (en) * | 2009-06-26 | 2013-05-07 | Massachusetts Institute Of Technology | Methods and compositions for increasing the activity of inhibitory RNA |
WO2010151664A2 (en) | 2009-06-26 | 2010-12-29 | Massachusetts Institute Of Technology | Compositions and methods for treating cancer and modulating stress granule formation |
US8268550B2 (en) * | 2009-06-26 | 2012-09-18 | Massachusetts Institute Of Technology | Compositions and methods for identification of PARP function, inhibitors, and activators |
WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
US20140315973A1 (en) * | 2010-10-07 | 2014-10-23 | Agency For Science, Technology And Research | Parp-1 inhibitors |
MX368261B (es) | 2011-07-22 | 2019-09-25 | Pacylex Pharmaceuticals Inc | Letalidad sintetica y el tratamiento de cancer. |
CA3080441A1 (en) | 2012-02-23 | 2013-09-06 | The Children's Hospital Corporation | Methods for predicting anti-cancer response |
EP2870140B8 (en) | 2012-07-09 | 2016-09-28 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
US20160040155A1 (en) * | 2013-04-16 | 2016-02-11 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
CN112522408A (zh) * | 2013-09-23 | 2021-03-19 | 芝加哥大学 | 关于dna损伤制剂用于癌症治疗的方法和组合物 |
USRE48856E1 (en) | 2014-02-07 | 2021-12-21 | Vib Vzw | Inhibition of NEAT1 for treatment of solid tumors |
US9889141B2 (en) | 2014-10-14 | 2018-02-13 | Institute For Cancer Research | Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer |
MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
WO2017011907A1 (en) | 2015-07-17 | 2017-01-26 | Pacylex Pharmaceuticals Inc. | Epigenetic silencing of nmt2 |
BR112018006263A2 (pt) | 2015-10-02 | 2018-10-16 | Memorial Sloan Kettering Cancer Center | inibidor de tonsl, molécula pequena, uso de uma molécula pequena ou de um inibidor, cristal tridimensional, métodos para selecionar ou desenhar uma molécula pequena, para identificar um inibidor de ligação de ard de tonsl à histona h4, para predizer o efeito de inibição de tonsl e para identificar um inibidor de tonsl e/ou determinar o efeito inibitório de um inibidor putativo de tonsl, sequência de polinucleotídeo ou sequência de aminoácidos isolada, e, polipeptídeo mutante de tonsl. |
DK3420080T3 (da) * | 2016-02-22 | 2019-11-25 | Caribou Biosciences Inc | Fremgangsmåde til modulering af dna-repair-resultater |
EP3535586A4 (en) * | 2016-11-01 | 2020-08-05 | AnaptysBio, Inc. | ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGUE LOBULIN AND MUCIN PROTEIN 3 (TIM-3) |
AU2018205401A1 (en) | 2017-01-09 | 2019-07-25 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
CN107058233A (zh) * | 2017-05-03 | 2017-08-18 | 上海长海医院 | 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法 |
CN108048465A (zh) * | 2017-12-20 | 2018-05-18 | 李风玲 | 一种抑制PARP基因用于治疗乳腺癌的siRNA |
WO2019133864A1 (en) | 2017-12-29 | 2019-07-04 | Accutar Biotechnology | DUAL INHIBITORS OF PARP1 and CDK |
MX2020007060A (es) | 2018-01-05 | 2020-11-11 | Cybrexa 1 Inc | Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas. |
US11607404B2 (en) * | 2019-03-25 | 2023-03-21 | Cyteir Therapeutics, Inc. | Combinations of RAD51 and PARP inhibitors |
EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
CA3161892A1 (en) | 2019-12-23 | 2021-07-01 | Jie Fan | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
KR20230002487A (ko) | 2020-04-28 | 2023-01-05 | 리젠 파마슈티컬스 아게 | 폴리(adp-리보스) 폴리머라제(parp) 억제제로서 유용한 신규 화합물 |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
CN114836472A (zh) * | 2021-02-01 | 2022-08-02 | 中国人民解放军军事科学院军事医学研究院 | PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用 |
MX2023011793A (es) | 2021-04-08 | 2023-10-12 | Rhizen Pharmaceuticals Ag | Inhibidores de poli(adenosin difosfato-ribosa) polimerasa. |
CA3219248A1 (en) | 2021-05-18 | 2022-11-24 | Hyun Ju Cha | Parp inhibitor-resistant cancer therapeutic agent |
WO2023089032A1 (en) * | 2021-11-19 | 2023-05-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5484951A (en) | 1990-10-19 | 1996-01-16 | Octamer, Incorporated | 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents |
US5098861A (en) | 1991-01-08 | 1992-03-24 | Unitrode Corporation | Method of processing a semiconductor substrate including silicide bonding |
US5464871A (en) | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
EP0600831A1 (de) | 1992-11-27 | 1994-06-08 | Ciba-Geigy Ag | Phthalazinonderivate |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
WO1999008680A1 (en) * | 1997-08-15 | 1999-02-25 | The Johns Hopkins University | Method of using selective parp inhibitors to prevent or treat neurotoxicity |
ATE261963T1 (de) * | 1999-01-11 | 2004-04-15 | Agouron Pharma | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
ECSP003637A (es) * | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
WO2002012239A1 (fr) * | 2000-08-08 | 2002-02-14 | Sanofi-Synthelabo | Derives de benzimidazole, leur preparation et leur application en therapeutique |
EA006300B1 (ru) | 2000-10-30 | 2005-10-27 | Кудос Фармасеутикалс Лимитед | Производные фталазинона |
DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
US7072771B2 (en) * | 2001-06-07 | 2006-07-04 | University Of Kentucky Research Foundation | Selective PARP-1 targeting for designing chemo/radio sensitizing agents |
US20030073692A1 (en) | 2001-08-07 | 2003-04-17 | Pharmacia & Upjohn S.P.A. | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
US20030229004A1 (en) | 2002-03-20 | 2003-12-11 | Pangene Corporation | Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors |
JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
AU2003253906A1 (en) | 2002-07-19 | 2004-02-09 | Osteotech, Inc. | Chisels and procedure for insertion of spinal implant in a spinal disc space |
GB2415430B (en) * | 2003-03-12 | 2006-07-12 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7176188B2 (en) | 2003-05-07 | 2007-02-13 | UniversitéLaval | Method of lethally sensitizing human and animal cells |
GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
DK1660095T3 (da) * | 2003-07-25 | 2010-05-25 | Cancer Rec Tech Ltd | Tricykliske PARP-inhibitorer |
RU2413515C2 (ru) | 2003-12-01 | 2011-03-10 | Кудос Фармасьютикалс Лимитед | Ингибиторы репарации повреждения днк для лечения рака |
-
2003
- 2003-07-25 GB GBGB0317466.1A patent/GB0317466D0/en not_active Ceased
-
2004
- 2004-07-23 GB GB0603874A patent/GB2419882B/en active Active
- 2004-07-23 KR KR1020067001650A patent/KR101136702B1/ko active Protection Beyond IP Right Term
- 2004-07-23 BR BRPI0412909-1A patent/BRPI0412909B1/pt active IP Right Grant
- 2004-07-23 ES ES04743564.9T patent/ES2367433T5/es active Active
- 2004-07-23 CN CN2004800273183A patent/CN1856313B/zh active Active
- 2004-07-23 US US10/555,507 patent/US8859562B2/en active Active
- 2004-07-23 CN CN2004800272941A patent/CN1856572B/zh active Active
- 2004-07-23 EP EP04743564.9A patent/EP1649017B2/en active Active
- 2004-07-23 WO PCT/GB2004/003235 patent/WO2005012524A1/en active Application Filing
- 2004-07-23 AT AT04743564T patent/ATE516353T1/de active
- 2004-07-23 PT PT04743564T patent/PT1649017E/pt unknown
- 2004-07-23 DK DK04743564.9T patent/DK1649017T4/da active
- 2004-07-23 CA CA2533423A patent/CA2533423C/en active Active
- 2004-07-23 NZ NZ545307A patent/NZ545307A/en unknown
- 2004-07-23 AU AU2004261779A patent/AU2004261779B2/en active Active
- 2004-07-23 JP JP2006520907A patent/JP5519097B2/ja active Active
- 2004-07-23 CN CN201210332472.8A patent/CN102935230B/zh active Active
- 2004-07-23 PL PL04743564T patent/PL1649017T5/pl unknown
-
2006
- 2006-02-16 ZA ZA200601386A patent/ZA200601386B/en unknown
- 2006-02-24 NO NO20060906A patent/NO338398B1/no unknown
-
2007
- 2007-01-10 HK HK07100334.8A patent/HK1094006A1/xx unknown
-
2011
- 2011-11-11 JP JP2011246988A patent/JP5547164B2/ja active Active
-
2013
- 2013-07-16 JP JP2013147532A patent/JP5848728B2/ja active Active
- 2013-08-12 HK HK13109407.3A patent/HK1182016A1/zh unknown
-
2014
- 2014-07-02 US US14/322,759 patent/US20150005327A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,459 patent/US20180000822A1/en not_active Abandoned
-
2019
- 2019-10-10 US US16/598,808 patent/US20200237762A1/en not_active Abandoned
-
2021
- 2021-11-16 US US17/528,034 patent/US20220062286A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220062286A1 (en) | Use of rnai inhibiting parp activity for the manufacture of a medicament for the treatment of cancer | |
AU2004261462B2 (en) | Tricyclic PARP inhibitors | |
MXPA06000953A (es) | Uso de arni que inhibe la actividad de parp para la manufactura de un medicamento para el tratamiento de cancer |